Browse > Article
http://dx.doi.org/10.7314/APJCP.2015.16.1.299

Clinical Study on Safety and Efficacy of JiSaiXin (Recombinant Human Granulocyte Colony Stimulating Factor Injection Manufactured in China) for Chinese Undergoing Chemotherapy  

Wang, Lin (Department of Chemotherapy, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University and Jiangsu Institute of Cancer Research)
Huang, Xin-En (Department of Chemotherapy, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University and Jiangsu Institute of Cancer Research)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.16, no.1, 2015 , pp. 299-301 More about this Journal
Abstract
Objectives: To assess safety and efficacy of JiSaiXin (Recombinant Human Granulocyte Colony Stimulating Factor Injection manufactured in China, G-CSF) 150ug per day for three days and whether this regimen could reduce the incidence of febrile neutropenia caused by chemotherapy. Method: From July 2014 to December 2014 patients treated by chemotherapy in our hospital were randomly divided into two groups: Group A with prophylactic use of G-CSF (JiSaiXin) 24 hours after chemotherapy for consecutive 3 days; and Group B with G-CSF (JiSaiXin) after neutropenia. Routine blood tests were performed 7 days and 14 days after chemotherapy. Results: A total of 100 patients fulfilled study criteria, and the incidence of severe neutropenia (grade III/IV) and the incidence of febrile neutropenia in Group A were lower than those in Group B. Nine patients were found severe neutropenia (grade III/IV) in Group B, but one in Group A, three febrile neutropenia in Group B, but 0 in Group A. Conclusions: This study suggested that prophylactic use of G-CSF (JiSaiXin) 150ug per day 24 hours after chemotherapy for consecutive 3 days is safe and could be effective for preventing febrile neutropenia in patients with chemotherapy.
Keywords
Prophylactic use; JiSaiXin; chemotherapy; febrile neutropenia;
Citations & Related Records
Times Cited By KSCI : 14  (Citation Analysis)
연도 인용수 순위
1 Cui L, Liu XX, one more author, et al (2014). Phase II study on dose escalating schedule of paclitaxel concurrent with radiotherapy in treating patients with locally advanced non-small cell lung cancer. Asian Pac J Cancer Prev, 15, 1699-702.   과학기술학회마을   DOI   ScienceOn
2 Deng QQ, Huang XE, Ye LH, et al (2013). Phase II trial of Loubo(R) (lobaplatin) and pemetrexed for patients with metastatic breast cancer not responding to anthracycline or taxanes. Asian Pac J Cancer Prev, 14, 413-7.   과학기술학회마을   DOI   ScienceOn
3 Gong JP, Yang L, one more author, et al (2014). Outcomes based on risk assessment of anastomotic leakage after rectal cancer surgery. Asian Pac J Cancer Prev, 15, 707-12.   과학기술학회마을   DOI   ScienceOn
4 Hou ZB, Lu KJ, one more author, et al (2014). In vitro and in vivo antitumor evaluation of berbamine for lung cancer treatment. Asian Pac J Cancer Prev, 15, 1767-9.   과학기술학회마을   DOI   ScienceOn
5 Huang XE, Cao J, one more author, et al (2014). Leucogen tablets at 60 mg three times per day are safe and effective to control febrile neutropenia. Asian Pac J Cancer Prev, 15, 8495-7.   과학기술학회마을   DOI
6 Huang XE, Tian GY, Cao J, et al (2013). Pemetrexed as a component of first-, second- and third-line chemotherapy in treating patients with metastatic lung adenocarcinoma. Asian Pac J Cancer Prev, 14, 6663-7.   과학기술학회마을   DOI   ScienceOn
7 Huang XE, Wei GL, Huo JG, et al (2013). Intrapleural or intraperitoneal lobaplatin for treatment of patients with malignant pleural effusion or ascites. Asian Pac J Cancer Prev, 14, 2611-4.   과학기술학회마을   DOI   ScienceOn
8 Kuderer NM, Dale DC, Crawford J, et al (2007). Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol, 25, 3158-67.   DOI
9 Kuderer NM, Dale DC, Crawford J, et al (2006). Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer, 106, 2258-66.   DOI
10 Lal A, Bhurgri Y, Rizvi N, et al (2008). Factors influencing in-hospital length of stay and mortality in cancer patients suffering from ferile neutropenia. Asian Pac J Cancer Prev, 9, 303-8.
11 Liu J, Huang XE, Feng JF et al (2014). Further study on pemetrexed based chemotherapy in treating patients with advanced gastric cancer (AGC). Asian Pac J Cancer Prev, 15, 6587-90.   과학기술학회마을   DOI
12 Liu J, Huang XE, Tian GY, et al (2013). Phase II Study on safety and efficacy of Yadanzi(R) (Javanica oil emulsion injection) combined with chemotherapy for patients with gastric cancer. Asian Pac J Cancer Prev, 14, 2009-12.   과학기술학회마을   DOI   ScienceOn
13 Lu YY, Huang XE, et al (2014). Clinical observations on associations between the UGT1A1 genotype and severe toxicity of irinotecan. Asian Pac J Cancer Prev, 15, 3335-41.   과학기술학회마을   DOI
14 Smith TC, Khatcheressian J, Lvman GH, et al (2006). Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline, J Clin Onco1, 24, 3187-205.   DOI
15 Tan HTK, Hurley D, Daniel G, et al (2011). Comparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective study. Curr Med Res Opin, 27, 79-6.   DOI
16 Tian GY, Miu M, Huang XE, et al (2014). Systematic analysis of pemetrexed-based chemoradiotherapy for patients with locally advanced or metastatic esophageal cancer. Asian Pac J Cancer Prev, 15, 8475-8.   과학기술학회마을   DOI
17 Weycker D, Malin J, Glass A, et al (2007). Economic burden of chemotherapy-related febrile neutropenia. J Support Oncol, 5, 44-5.
18 Weycker DMJ, Barron R, Edelsberg J, et al (2011). Comparative effectiveness of filgrastim, pegfilgrastim, and sargramostim as prophylaxis against hospitalization for neutropenic complications in patients with cancer receiving chemotherapy. Am J Clin Oncol, 35, 267-74.
19 Wu XY, Huang XE, You SX, et al (2013). Phase II study of pemetrexed as second or third line combined chemotherapy in patients with colorectal cancer. Asian Pac J Cancer Prev, 14, 2019-22.   과학기술학회마을   DOI   ScienceOn
20 Xu C, Lv PH, one more author, et al (2014). Safety and efficacy of sequential transcatheter arterial chemoembolization and portal vein embolization prior to major hepatectomy for patients with HCC. Asian Pac J Cancer Prev, 15, 703-6.   과학기술학회마을   DOI   ScienceOn
21 Yan HA, Shen K, Huang XE (2013). Clinical study on mannan peptide combined with TP regimen in treating patients with non-small cell lung cancer. Asian Pac J Cancer Prev, 14, 4801-4.   과학기술학회마을   DOI   ScienceOn
22 Zhang Jing, Yu Shiying , et al (2014). The current G-CSF use in cancer patients with chemotherapy. Chinese-German J Clin Oncol, 13, 6.
23 Caggiano V, Weiss RV, Rickert TS, et al (2005). 1ncidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy.Cancer, 103, 1916-24.   DOI